Erythropoiesis-stimulating agents – REMS removal
April 13, 2017 – The FDA announced that the risk evaluation and mitigation strategy (REMS) requirement for the erythropoiesis-stimulating agents (ESAs), epoetin alfa (Procrit®, Epogen®) and darbepoetin alfa (Aranesp®), regarding their use in patients with anemia due to chemotherapy, is no longer necessary.
Top